Noa Therapeutics
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Noa Therapeutics - overview
Established
2022
Location
Toronto, ON, Canada
Primary Industry
Biotechnology
About
Founded in 2022 and based in Toronto, Ontario, Canada, Noa Therapeutics operates as a biotechnology platform that engages in developing a treatment of inflammatory disease. In March 2024, Noa Therapeutics raised pre-seed funding led by UCeed Haskayne Student Fund, with participation from Archangel, NorthSpring Capital Partners, Ontario Centre of Innovation, and Phoenix Fire. Noa Therapeutics is a company developing new treatments for immune diseases, especially those that affect the skin and gut barrier. Their approach is different from current treatments because it aims to address multiple aspects of the disease at once, rather than just focusing on symptoms.
They are working on a new drug called NOA-104 that would target three disease drivers at the same time. The company plans to use the March 2024 funding to support its clinical trials for inflammatory disease treatment.
Current Investors
Ontario Centre of Innovation, NorthSpring Capital Partners, Archangel
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.noatherapeutics.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Noa Therapeutics - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.